Merck Sharp & Dohme (MSD) on Friday said its COVID antiviral molnupiravir has cut the risk of hospitalization or death in Phase 3 clinical ...

Molnupiravir is for treatment of adult patients hospitalised with COVID-19, under certain conditions, a press release from the city-based d...

The full treatment of Molulife (brand name) is expected to cost ₹1,400, RC Juneja, chairman of Mankind Pharma, told ET. The brand is expect...

Drug maker Cipla said it will soon make molnupiravir capsules available at all leading pharmacies and Covid treatment centers across the co...

Torrent Pharmaceuticals on Tuesday said it will launch MSD and Ridgeback's molnupiravir under the brand name Molnutor in India for the trea...

Earlier this year, the Mumbai-based drug major had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply ...

The USFDA also said molnupiravir should be given to those for whom alternative Covid-19 treatment options authorised by it are not accessib...

The USFDA also said the drug should be given for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or cl...

The analysis of latest data on efficacy is much less than the previous interim analysis announced by the company which was based on data fr...

The firms whose applications that will be taken up are Dr Reddy's Laboratories which has filed for approval in a consortium with five other...

The company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...

The MHRA recommended the use of Covid-19 drug molnupiravir as soon as possible following a positive Covid-19 test and within five days of s...

The risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease. MHRA recommended the use of Molnupiravir as s...

Under the terms of the agreement, MPP will be permitted to further license non-exclusive sub-licences to manufacturers and diversify the ma...

The clinical trial will be conducted for the treatment of mild COVID-19 in an outpatient setting and is expected to take place between June...

MSD entered into a voluntary licensing agreement with five Indian drug makers including Sun Pharma, Cipla, Dr. Reddy’s, Emcure and Hetero f...

MSD has decided to enter into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generic manufactur...